Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Operating Margin
Avadel Pharmaceuticals PLC
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IE |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
873.6m USD |
-10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
374.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.9B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
191.1B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.2B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
204.7B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
185.4B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
27%
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Avadel Pharmaceuticals PLC's most recent financial statements, the company has Operating Margin of -10%.
You don't have any saved screeners yet